巴楚医学

目的：挖掘米氮平引起睡眠相关不良事件的风险信号以及影响因素，为临床科学使用米氮平提供依据。方法：采集2004-2019年美国FDA不良事件报告系统(FAERS)数据，利用报告比值比法(ROR)和贝叶斯可信区间递进神经网络法(BCPNN)检测睡眠相关不良事件风险信号，并采用Logistic回归分析对其影响因素。结果：提取出68个睡眠相关不良事件，ROR法和BCPNN法筛选出21个共同睡眠相关不良事件风险信号，Logistic回归分析显示性别(OR=1.018,95%CI:1.006,1.030)和年龄(OR=0.999,95%CI:0.998,0.999)是米氮平发生睡眠相关不良事件的影响因素。结论：米氮平可致睡眠相关不良事件的发生，且女性和高龄可增加发生风险。

Objective: To excavate the risk signals and influence factors of sleep-related adverse events caused by mirtazapine, and provide reference for scientific use of mirtazapine in clinic. Methods: The data of FDA's adverse event reporting system(FAERS) from 2004 to 2019 were collected. Risk signals of sleep-related adverse events were detected using the report-to-ratio method(ROR) and Bayesian confidence interval progressive neural network method(BCPNN). Logistic regression was used for multivariate analysis. Results: A total of 68 sleep-related adverse events were extracted. There were 21 common risk signals for sleep-related adverse event screened out by ROR and BCPNN methods. Logistic regression analysis indicated that gender(OR=1.018,95% CI: 1.006,1.030) and age(OR=0.999,95% CI: 0.998,0.999) were influence factors for sleep-related adverse events induced by mirtazapine. Conclusion: Mirtazapine can cause sleep-related adverse events, which may be increased by women and advanced age.